Not applicableStudy completedNCT06178770
What this trial is testing
Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 414